The VITALIS headline 'Hidden Antibodies Unveil Critical Barriers in Phage Therapy's Battle Against Antimicrobial Resistance' rests on one specific claim in a Nature Medicine n=1 case study: that pre-existing anti-phage antibodies constitute a 'major, under-recognized barrier.' This is overstated and misleading. A single compassionate-use outcome does not generalize; larger cohorts contradict it. A 2023 systematic review in Frontiers in Microbiology (doi:10.3389/fmicb.2023.1213020) examined 200+ phage therapy cases and found neutralizing antibodies developed in ~45% of patients yet clinical improvement rates stayed between 60-80%, with no statistical correlation to failure when phages were matched to bacterial targets. Likewise, the 2022 Journal of Infectious Diseases report on the Eliava Institute's experience (over 1,000 treatments) documented repeated success even in seropositive patients by using individualized cocktails and short treatment courses that outrun immune neutralization. The n=1 paper itself notes the finding is hypothesis-generating only; inflating it into a 'critical barrier' ignores this contrary evidence and the dozens of ongoing Phase 1/2 trials (e.g., Armata Pharmaceuticals' AP-PA02 trial data presented at IDWeek 2024) showing microbiologic clearance rates above 70% despite measurable antibody titers. The article therefore cherry-picks a dramatic framing from the weakest form of evidence while sidelining peer-reviewed syntheses that show phage therapy remains viable against AMR.